Cargando…
Biomarkers and Surrogate Endpoints: How and When might They Impact Drug Development?
As the pharmaceutical industry starts developing novel molecules developed based on molecular biology principles and a better understanding of the human genome, it becomes increasingly important to develop early indicators of activity and/or toxicity. Biomarkers are measurements based on molecular p...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
IOS Press
2002
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850863/ https://www.ncbi.nlm.nih.gov/pubmed/12364814 http://dx.doi.org/10.1155/2002/438745 |